A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-06-22
Target enrollment:
Participant gender:
Summary
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors.
This study is a single-arm, prospective, open label clinical study of pyrotinib plus
vinorelbine as the therapy of brain metastases from HER2-positive metastatic breast cancer.